Figure 7. No evidence of increased viral expression following repeated GS-9620 administration.

(A) Plasma viral loads prior to and during the first course of GS-9620 administration (doses 1.1 to 1.12). Red arrows indicate GS-9620 administrations at 0.15 mg/kg for the first two doses (1.1 and 1.2) and at 0.5 mg/kg for the last 10 doses (1.3 to 1.12). The 15-vRNA copy/ml threshold sensitivity of the viral load assay used is shown. Also shown for reference is the 50-vRNA copy/ml threshold sensitivity of the assay used in ref. 39. Dose 1.1 (time point 0) corresponds to 75 weeks after infection (wpi), or 73 weeks after cART initiation. (B and C) Cell/tissue-associated vRNA and vDNA content were quantified within the same samples by qRT-PCR and qPCR and the ratio of these values calculated. The calculated ratio in PBMC samples collected immediately prior to (Before) and at 24 hours and 48 hours following each of the 12 doses of the first course of GS-9620 (doses 1.1 through 1.12) are shown in B. The calculated ratio in LN, duodenal, and rectal tissue specimens collected and snap frozen prior to the first dose of GS-9620 (Before) and at 24 hours and 48 hours following dose 1.9 are shown in C. For A–C, GS-9620–treated animals are shown with red plot symbols and vehicle control animals are shown with blue plot symbols.